Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Relapsed or Refractory Myeloma
NCT01866293Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2013
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2013; status: completed.
02
Drugs
cabozantinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01866293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01866293.